A Phase 1 interventional study of 131I-MIBG and Dinutuximab in Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium. Completed at 12 sites in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2025-04-16.
Sponsored by New Approaches to Neuroblastoma Therapy Consortium · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing dinutuximab in Neuroblastoma — 9 open to participants now, 14 under way, 4 of them phase 3. dinutuximab · Neuroblastoma.
Among the 27 studies testing dinutuximab in Neuroblastoma, this one is the 11th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 1, and was the 14th registered.
676 studies on the registry are indexed under Neuroblastoma; 128 are open to participants now.
Browse Neuroblastoma studies →9 of the 27 studies testing dinutuximab in Neuroblastoma are open now, in 12 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 1–30
Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Sites in Russia
Ages 18 mo–18 yrs
New Approaches to Neuroblastoma Therapy Consortium · Sites in United States
Ages 1–31
University of Birmingham · Sites in Australia, Austria, Belgium and 2 more countries
Ages 1+
National Cancer Institute (NCI) · Sites in United States, Australia, Canada and 2 more countries
Ages up to 30
By country, each count listing its studies:
dinutuximab: first FDA approval 2015 (UNITUXIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 105 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 75 (71%) stop at 75 or younger; 102 take children under 18; 3 take healthy volunteers.
This study: 1 Year to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 6
First in 2001; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is above the median of 33 across 508 interventional studies indexed under Neuroblastoma.
Median enrollment 35 across the 27 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 27 have an industry lead sponsor. The 10 most frequent:
New Approaches to Neuroblastoma Therapy Consortium is the lead sponsor of 24 studies on the registry; 3 are open to participants now.
24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium: 3 open now, 6 under way, none of them phase 3. Of 18 finished, 5 (28%) have results posted.
Among the 24 studies in Neuroblastoma by New Approaches to Neuroblastoma Therapy Consortium, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2018, is one of 17 in phase 1, and was the 22nd registered.
New Approaches to Neuroblastoma Therapy Consortium’s Neuroblastoma studies by the year they started, since 1996.
4 of the studies testing dinutuximab in Neuroblastoma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04221035Phase 3Gustave Roussy, Cancer Campus, Grand ParisHigh-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | 2026-11 |
| NCT07375563Phase 3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyChemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma | 2026-12-15 |
| NCT04211675Nationwide Children's HospitalNK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | 2026-12 |
| NCT02573896New Approaches to Neuroblastoma Therapy ConsortiumImmunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | 2026-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies testing dinutuximab in Neuroblastoma, from their registry updates:
Among New Approaches to Neuroblastoma Therapy Consortium’s 24 in Neuroblastoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease. In this pediatric phase 1 trial, 131I-MIBG will be given in combination with dinutuximab, a chimeric 14.18 monoclonal antibody. This study will utilize a traditional Phase I rolling 6 dose escalation design to determine a recommended phase 2 pediatric dose. An expansion cohort of an additional 6 patients will then be enrolled. If tolerable, vorinostat will then be added to the third dose level. A 6 patient expansion cohort may then be enrolled.
131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease. Data from pre-clinical and adult studies suggest that radiation can enhance the efficacy of immunotherapy and targeted therapies such as dinutuximab. This first pediatric phase 1 trial of 131I-MIBG in combination with dinutuximab and vorinostat aims to determine the recommended phase 2 pediatric dose of these three therapies in combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients must have at least one of the following
No prior history of recurrent/progressive disease since the diagnosis of high risk neuroblastoma b1) disease- a best overall response of no response/stable disease since diagnosis of high risk neuroblastoma and at least 4 cycles of induction therapy. No prior history of recurrent/progressive disease since the diagnosis of high risk neuroblastoma.
b2) Persistent disease- a best overall response of no partial response since diagnosis of high risk neuroblastoma and at least 4 cycles of induction therapy. No prior history of recurrent/progressive disease since the diagnosis of high risk neuroblastoma.
Patients must have at least ONE of the following (lesions may have received prior radiation therapy as long as they meet the other criteria listed below):
a) For recurrent/progressive or refractory disease, at least one MIBG avid bone site.
b) For persistent disease, if a patient has 3 or more MIBG avid lesions, then no is required. If a patients has only 1 or 2 MIBG avid bone lesion sites then biopsy confirmation of neuroblastoma or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required to be obtained at any time point prior to enrollment.
c) For MIBG non-avid tumors, patients must have at least one FDG avid site and a biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment from at least one FDG-avid site.
At least one soft tissue lesion that meets criteria for a TARGET lesion as defined by:
a) SIZE: Lesion can be accurately measured in at least one dimension with a longest diameter ≥ 10 mm, or for lymph nodes ≥ 15 mm on short axis. Lesions meeting size criteria will be considered measurable.
b) In addition to size, a lesion needs to meet one of the following criteria except for patients with parenchymal CNS lesions which only need to meet size criteria: b1) MIBG avid. For patients with recurrent/progressive or refractory disease, no biopsy is required. For patients with persistent disease only: If a patient has only 1 or 2 MIBG avid lesions sites, then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at time of enrollment is required to be obtained. If a patient has 3 or more MIBG avid lesions, then no biopsy is required.
b2) MIBG non avid tumors: Patients must have at least one FDG avid site and biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one FDG-PET avid site present at the time of enrollment.
Patients with known bone marrow disease will be eligible for study as long as they meet hematologic function criteria above.
Pulmonary Function: No dyspnea at rest, no oxygen requirement.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive 131I-MIBG on day 1 at 12 mCi/kg/dose. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy at 17.5 mg/m2/dose. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
Radiation: 131I-MIBG · Drug: Dinutuximab · Drug: Sargramostim · Drug: Potassium Iodide
Patients will receive 131I-MIBG on day 1 at 15 mCi/kg/dose. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy at 17.5 mg/m2/dose. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
Radiation: 131I-MIBG · Drug: Dinutuximab · Drug: Sargramostim · Drug: Potassium Iodide
Patients will receive 131I-MIBG on day 1 at 18 mCi/kg/dose. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy at 17.5 mg/m2/dose. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
Radiation: 131I-MIBG · Drug: Dinutuximab · Drug: Sargramostim · Drug: Potassium Iodide
Vorinostat will be given on days 0-13 at 180 mg/m2/dose. Patients will receive 131I-MIBG on day 1 at 18 mCi/kg/dose. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy at 17.5 mg/m2/dose. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
Radiation: 131I-MIBG · Drug: Dinutuximab · Drug: Vorinostat · Drug: Sargramostim · Drug: Potassium Iodide
Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
Also known as: 131I-Metaiodobenzylguanidine, Iobenguane sulfate, m-Iodobenzylguanidine sulfate, MIBG
Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
Also known as: Chimeric Monoclonal Antibody 14.18, MAB Ch 14.18, Unituxin, Ch14.18
Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.
Also known as: Zolina
Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2
Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
MTD/RP2D Determination Cohort A
Proportion of patients with Course 1 DLT in Cohort A
Time frame: All toxicities from enrollment until completion of course 1 (Day 56)
MTD/RP2D Determination Cohort B
Proportion of patients with Course 1 DLT in Cohort B
Time frame: All toxicities from enrollment until completion of course 1 (Day 56)
Describe Non-Hematological Toxicities Cohort A
Proportion of patients with any grade 3 or greater non-hematological toxicities in Cohort A
Time frame: All toxicities from enrollment through 30 days following end of protocol therapy, up to 5 months
Describe Non Hematological Toxicities Cohort B
Proportion of patients with any grade 3 or greater non-hematological toxicities in Cohort B
Time frame: All toxicities from enrollment through 30 days following end of protocol therapy, up to 5 months
Overall Response Cohort A
Proportion of patients evaluable for response with a best overall response of CR/CR-MD/PR for patients in Cohort A
Time frame: From Day 1 of protocol therapy through 30 days following end of protocol therapy, up to 5 months
Overall Response Cohort B
Proportion of patients evaluable for response with a best overall response of CR/CR-MD/PR for patients in Cohort B
Time frame: From Day 1 of protocol therapy through 30 days following end of protocol therapy, up to 5 months
| Milestone | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 | Cohort B DL4 |
|---|---|---|---|---|
| Started | 6 | 5 | 20 | 14 |
| Completed | 1 | 2 | 6 | 11 |
| Not completed | 5 | 3 | 14 | 3 |
| Withdrew: Adverse event | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 5 | 1 |
| Withdrew: Disease progression or relapse | 2 | 1 | 3 | 0 |
| Withdrew: Initiation onto another anti-cancer therapy | 1 | 1 | 3 | 1 |
| Withdrew: No treatment received | 0 | 0 | 1 | 0 |
Proportion of patients with Course 1 DLT in Cohort A
| Participants | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 |
|---|---|---|---|
| MTD/RP2D Determination Cohort A | 0 | 0 | 0 |
Proportion of patients with Course 1 DLT in Cohort B
| Participants | Cohort B DL4 |
|---|---|
| MTD/RP2D Determination Cohort B | 1 |
Proportion of patients with any grade 3 or greater non-hematological toxicities in Cohort A
| Participants | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 |
|---|---|---|---|
| Describe Non-Hematological Toxicities Cohort A | 5 | 3 | 10 |
Proportion of patients with any grade 3 or greater non-hematological toxicities in Cohort B
| Participants | Cohort B DL4 |
|---|---|
| Describe Non Hematological Toxicities Cohort B | 12 |
Proportion of patients evaluable for response with a best overall response of CR/CR-MD/PR for patients in Cohort A
| Participants | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 |
|---|---|---|---|
| Overall Response Cohort A | 2 | 4 | 5 |
Proportion of patients evaluable for response with a best overall response of CR/CR-MD/PR for patients in Cohort B
| Participants | Cohort B DL4 |
|---|---|
| Overall Response Cohort B | 5 |
Collected over All adverse events from enrollment through 30 days following end of protocol therapy, up to 5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A DL1 | 4/6 (66.7%) | 3/6 (50%) | 6/6 (100%) |
| Cohort A DL2 | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Cohort A DL3 | 12/20 (60%) | 6/20 (30%) | 19/20 (95%) |
| Cohort B DL4 | 5/14 (35.7%) | 8/14 (57.1%) | 14/14 (100%) |
| Event | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 | Cohort B DL4 |
|---|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 0/6 | 1/5 | 0/20 | 4/14 |
| FeverGeneral disorders | 0/6 | 1/5 | 0/20 | 2/14 |
| Urinary tract painRenal and urinary disorders | 0/6 | 1/5 | 0/20 | 0/14 |
| Jejunal obstructionGastrointestinal disorders | 1/6 | 0/5 | 0/20 | 0/14 |
| Platelet count decreasedInvestigations | 1/6 | 0/5 | 0/20 | 0/14 |
| Tumor painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/5 | 0/20 | 1/14 |
| Spinal cord compressionNervous system disorders | 1/6 | 0/5 | 0/20 | 0/14 |
| Urinary retentionRenal and urinary disorders | 1/6 | 0/5 | 0/20 | 0/14 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/5 | 0/20 | 2/14 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/6 | 0/5 | 0/20 | 1/14 |
| Event | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 | Cohort B DL4 |
|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 6/6 | 4/5 | 16/20 | 12/14 |
| VomitingGastrointestinal disorders | 3/6 | 5/5 | 10/20 | 12/14 |
| Lymphocyte count decreasedInvestigations | 6/6 | 5/5 | 16/20 | 14/14 |
| Platelet count decreasedInvestigations | 5/6 | 5/5 | 16/20 | 13/14 |
| White blood cell decreasedInvestigations | 6/6 | 5/5 | 18/20 | 13/14 |
| HypoalbuminemiaMetabolism and nutrition disorders | 5/6 | 5/5 | 13/20 | 12/14 |
| Neutrophil count decreasedInvestigations | 5/6 | 3/5 | 15/20 | 13/14 |
| NauseaGastrointestinal disorders | 3/6 | 2/5 | 14/20 | 12/14 |
| HypocalcemiaMetabolism and nutrition disorders | 5/6 | 4/5 | 10/20 | 12/14 |
| Sinus tachycardiaCardiac disorders | 5/6 | 2/5 | 9/20 | 7/14 |
| Age, Categorical(Participants) | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 | Cohort B DL4 | Total |
|---|---|---|---|---|---|
| <=18 years | 5 | 5 | 19 | 11 | 40 |
| Between 18 and 65 years | 1 | 0 | 1 | 3 | 5 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 | Cohort B DL4 | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 7 | 7 | 18 |
| Male | 4 | 3 | 13 | 7 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 | Cohort B DL4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 3 | 1 | 8 |
| Not Hispanic or Latino | 4 | 2 | 14 | 13 | 33 |
| Unknown or Not Reported | 1 | 0 | 3 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Cohort A DL1 | Cohort A DL2 | Cohort A DL3 | Cohort B DL4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 | 2 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 3 | 2 | 5 |
| White | 5 | 3 | 12 | 9 | 29 |
| More than one race | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 2 | 4 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Sep 2018 to primary completion in Feb 2024, 65 months.
Results were first posted in Apr 2025, 1 year 1 month after primary completion.
Of 73 non-industry phase 1 interventional studies under Neuroblastoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 117. This study's 65 months is below that.
Counting every sponsor, half of 86 studies reached it within 83 months; a quarter within 60 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium